Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
85.21B
Market cap85.21B
Price-Earnings ratio
20.46
Price-Earnings ratio20.46
Dividend yield
0.45%
Dividend yield0.45%
Average volume
640.21K
Average volume640.21K
High today
$841.53
High today$841.53
Low today
$825.83
Low today$825.83
Open price
$832.06
Open price$832.06
Volume
535.17K
Volume535.17K
52 Week high
$859.34
52 Week high$859.34
52 Week low
$541.00
52 Week low$541.00

Stock Snapshot

With a market cap of 85.21B, Regeneron(REGN) trades at $827.72. The stock has a price-to-earnings ratio of 20.46 and currently yields dividends of 0.45%.

As of 2026-09-05, Regeneron(REGN) stock has fluctuated between $825.83 and $841.53. The current price stands at $827.72, placing the stock +0.2% above today's low and -1.6% off the high.

Regeneron(REGN) shares are trading with a volume of 535.17K, against a daily average of 640.21K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

REGN News

The Motley Fool 21h
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool

...

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
TipRanks 3d
Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion: What Investors Should Watch

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. The Phase 1/2 study A Phase 1/2, Open-label Study Evaluating the Safety,...

Simply Wall St 5d
Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has secured past FDA approval for Pasatru (garetosmab-grts), a VelocImmune-derived monoclonal antibody that reduces new heterotopic os...

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals?

Analyst ratings

62%

of 29 ratings
Buy
62.1%
Hold
31%
Sell
6.9%

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.